Levy Wealth Management Group’s Soleno Therapeutics SLNO Stock Holding History

Levy Wealth Management Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-667	Closed	-$2K	–	83
2022 Q2	$2K	Hold	667	–	–	﹤0.01%	69
2022 Q1	$2K	Hold	667	–	–	﹤0.01%	76
2021 Q4	$4K	Hold	667	–	–	﹤0.01%	77
2021 Q3	$9K	Hold	667	–	–	﹤0.01%	67
2021 Q2	$11K	Hold	667	–	–	0.01%	69
2021 Q1	$13K	Hold	667	–	–	0.01%	67
2020 Q4	$19K	Buy	+667	New	+$19.3K	0.01%	61

Other funds holding SLNO

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Clayton Partners Berkeley, California $138M AUM 38.58% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Levy Wealth Management Group's SLNO Position: Q3 2022 in Review

Levy Wealth Management Group sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 667 shares — an estimated $2K sold.

Levy Wealth Management Group first reported a position in SLNO in Q4 2020 and held it in 7 quarters. The position peaked at $19K in Q4 2020. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

Levy Wealth Management Group reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
Levy Wealth Management Group sold 667 Soleno Therapeutics shares in Q3 2022, an estimated $2K.
Levy Wealth Management Group first reported a position in Soleno Therapeutics in Q4 2020 and held it in 7 quarters.
Levy Wealth Management Group's Soleno Therapeutics position peaked at $19K in Q4 2020.
22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Levy Wealth Management Group's 13F filing for Q3 2022, filed 28 Oct 2022.